Kidswell Bio Corporation (4584)

Market cap
¥12B
P/E ratio
KidsWell Bio develops biosimilar drugs and regenerative medicine treatments using SQ-SHED stem cells from baby teeth for pharmaceutical partners and rare disease patients.
Period EndOperating margin (%) YoY (%)
Mar 31, 20250.5-101.00%
Mar 31, 2024-54.9+176.83%
Mar 31, 2023-19.8-66.12%
Mar 31, 2022-58.6-39.81%
Mar 31, 2021-97.3-9.70%
Mar 31, 2020-107.8+36.68%
Mar 31, 2019-78.8-8.53%
Mar 31, 2018-86.2-20.72%
Mar 31, 2017-108.7+53.87%
Mar 31, 2016-70.7-72.42%
Mar 31, 2015-256.2
AI Chat